General Considerations and of Protocol of Phase II Clinical Trial for Marketing Applications
R. Hamish McAllister-Williams,Daniel Bertrand,Hans Rollema,Raymond S. Hurst,Linda P. Spear,Tim C. Kirkham,Thomas Steckler,Delphine Capdevielle,Jean-Philippe Boulenger,Delphine Capdevielle,Jean-Philippe Boulenger,Delphine Capdevielle,Jean-Philippe Boulenger,Cyril Höschl,Martine Cador,Ben J. Harrison,Christos Pantelis,Anthony Riley,Steve Kohut,Alex Hofer,Ben J. Harrison,Christos Pantelis,Seithikurippu R. Pandi-Perumal,D. Warren Spence,Shelby Freedman Harris,Michael J. Thorpy,Milton Kramer,Ian Stolerman,Holden D. Brown,Michael Ragozzino,Klaus A. Miczek,Anne Jackson,Sven Ove Ögren,Oliver Stiedl,Paul R. Pentel,Mark LeSage,Victoria L. Harvey,Tony Dickenson,Christine A. Franco,Marc N. Potenza,Gail Winger,Mei-Chuan Ko,James H. Woods,Matthew I. Palmatier,Rick A. Bevins,Stephan G. Anagnostaras,Jennifer R. Sage,Stephanie A. Carmack,Jos Prickaerts,Jos Prickaerts,Jos Prickaerts,Warren H. Meck,Catalin V. Buhushi,Christoph U. Correll,Ian Stolerman,Mohammed Shoaib,Trevor Robbins,Daniel Hoyer,Thomas Steckler,Linda P. Spear,Luzio Tremolizzo,Gessica Sala,Carlo Ferrarese,Seiya Miyamoto,Thomas Steckler,David S. Tait,Verity J. Brown,Richard A. Depue,Tara L. White,Craig A. Erickson,David J. Posey,Kelly Blankenship,Kimberly A. Stigler,Christopher J. McDougle,Craig A. Erickson,David J. Posey,Kelly Blankenship,Kimberly A. Stigler,Christopher J. McDougle,Ian Stolerman,Jean-Michel Scherrmann,S. Stevens Negus,Dana E. Selley,Laura J. Sim-Selley,Christoph Hiemke,Sophie Tambour,John C. Crabbe,Pierre Baumann,Kim Wolff,Christof Baltes,Thomas Mueggler,Markus Rudin,Alan J. Budney,Robert L. Balster,Sharon Walsh,Robert L. Balster,Sharon Walsh,Robert L. Balster,Sharon Walsh,Andrea Bari,Johannes Mosbacher,Paul Willner,Klaus A. Miczek,Trevor Robbins,Wolfgang Fleischhacker,Etienne Sibille,Nicole Edgar,Sabine M. Hölter,John F. Cryan,Michel Le Moal,Marco Leyton,Sara Tomlinson,Glen Baker,Bernard Le Foll,Naheed (Max) Mirza,Tomasz Schneider,Jos Prickaerts,Jos Prickaerts,Robert L. Balster,Sharon Walsh,Yogita Chudasama,Thomas Steckler,Thomas Steckler,Daniel Hoyer,Stan Floresco,Christine A. Franco,Marc Potenza,Fabrizio Benedetti,Peter Riederer,Siegfried Hoyer,Luzio Tremolizzo,Gessica Sala,Carlo Ferrarese,Luzio Tremolizzo,Gessica Sala,Carlo Ferrarese,Lucio Tremolizzo,Gessica Sala,Carlo Ferrarese,Arthur Christopoulos,Gregory D. Stewart,Patrick M. Sexton,Christoph Hiemke,Malcolm Lader,Stefan Leucht,Mark Slifstein,Linda P. Spear,Samuel G. Siris,Susan Jones,Peter Verheart,Per Svenningsson,Per Andrén,Seithikurippu R. Pandi-Perumal,Milton Kramer,Michael J. Thorpy,Shelby Freedman Harris,D. Warren Spence,John Atack,Hilde Lavreysen,Stephen C. Fowler,Harriet de Wit,Britta Hahn,Stephen C. Fowler,Helen Cassaday,Paul Willner,Darren R. Christensen,Warren K. Bickel,Michael Minzenberg,David Baldwin,C. Neill Epperson,C. Neill Epperson,Lawrence Scahill,I. T. Uzbay,Lisiane Bizarro,Bart Ellenbroek,Linda P. Spear,Patrick D. McGorry,Alison R. Yung,Mark A. Geyer,Johannes Mosbacher,Malcolm Lader,Angela Roberts,Celia Morgan,Valerie Curran,Christine A. Franco,Marc Potenza,Celia Morgan,Valerie Curran,Thomas Steckler,Harriet de Wit,Jill B. Becker,Mary Cain,Michael T. Bardo,Thomas Steckler,Trevor Robbins,Theodora Duka,Sam Hutton,C. Neill Epperson,Celia Morgan,Valerie Curran,Gail Winger,Mei-Chuan Ko,James H. Woods,Peter Verheart,Per Svenningsson,Per Andrén,Martin Cammarota,Lia R. Bevilaqua,Iván Izquierdo,Husseini Manji,Jorge Quiroz,Per E. Andrén,Peter Verhaert,Per Svenningsson,Joji Suzuki,Torsten Passie,Pedro E. Huertas,John Halpern,Etienne Sibille,Nicole Edgar,Gorkem Yararbas,Sakire Pogun,Giovanni Hernandez,Peter Shizgal,Ian Hindmarch,Ian Hindmarch,Grasielle C. Kincheski,Leandro J. Bertoglio,Antonio Padua Carobrez,R. Hamish McAllister-Williams,Wiepke Cahn,Heleen B. M. Boos,H. D. Postma,Gabriele Fischer,Annemarie Unger,Marcy J. Bubar,Kathryn A. Cunningham,Kathryn A. Cunningham,Marcy J. Bubar,Marie-Louise Wadenberg,Jos Prickaerts,Marc N. Branch,Jeffrey M. Witkin,James E. Barrett,Ivan Izquierdo,Lia Rejane M. Bevilaqua,Martin Cammarota
2000-01-01
Abstract:This document describes the objectives, design, methodology, statisticalconsiderations, and organization of a clinical trial for marketing applications. The protocolwas designed and provided by sponsors in Europe and America, and by clinical trialresearchers in China. The protocol should be scientifically sound and carefully consideredbecause it plays a most important role in clinical trials. The clinical trial researchers mustrefer to the pharmacological and toxicological reports, and other related results of the drug.The protocol usually also gives the background and rationality for the trial with literaturereferences. According to Good Clinical Practice(GCP) of ICH-E6 and SDA, this paperproposed the general considerations in writing protocol and contents of protocol for phraseⅡ clinical trial. It had great reference value and can be utilized for phrase Ⅲ and Ⅳ clinicaltrials.
What problem does this paper attempt to address?
-
Protection of Human Rights in Clinical Trials
SHAN Wei,CONG Hang-qing
2011-01-01
Abstract:With the growing legal consciousness of nation,the contradiction in the clinical trials appears gradually.Researchers and subjects face many complicated problems.In that case,the clinical investigators and patients should clearly know their rights and obligations.Then,we should propose the practical ways to protect patients.There are three ways:(1) Medical Ethics Committee set up a position and the staff should track every stage of the clinical trial;(2) Regular doctor should provide professional advices to patients and let them know the effect of the clinical trial;(3) Improvement the registry of clinical trials as soon as possible.
-
Practice and Consideration of Master Protocol in Clinical Trials
Jiali Song,Zhiwei Rong,Xinwen Zhong,Yuhong Lu,Jike Huang,Yipei Yu,Zhilin Liu,Xuyuan Quan,Nana Chen,Kang Li,Fengyu Sun,Yan Hou
DOI: https://doi.org/10.36922/td.342
2023-01-01
Abstract:There is great interest in accelerating late-stage therapy development by efficiently performing a trial design with multiple therapies or multiple subpopulations simultaneously under a single protocol. The master protocols are termed to describe the design of such trials, with a variety of terms such as umbrella, basket, or platform describing specific designs, which are, in contrast to the traditional trial designs, full of complexity. What should we consider in designing a trial ensuring the safety of human subjects and demonstrating the efficacy of new therapy? This paper overviews the master protocol framework, comprehensively unifies the definitions and illustrates essential design elements of representative example trials conducted in drugs and medical devices. Besides, to understand the master protocols deeply, it is also a need to summarize the commonly-used types of master protocols in various disease and treatment fields, along with the reasons for these phenomena by analyzing the characteristics of the diseases, the mechanism of therapeutic products, and the principles of various types of master protocols. Finally, we also propose practical considerations, including the design, ethical, statistics, and funding considerations that arise from implementing complex master protocols to help practitioners better design and identify potential valuable therapies.
-
Consideration on Phase Ⅰ Clinical Trial Design for Anticancer Drugs
陈晓媛,王海学,钱思源,彭健
DOI: https://doi.org/10.3969/j.issn.1001-6821.2009.02.027
2009-01-01
Abstract:Phase Ⅱ clinical studies play a important role in drug clinical development.Well-designed phase Ⅱclinical trial and developing strategy is helpful to screen the compound with low effect or high toxicity more earlier,and select good candidate drug into large scale phase Ⅲ clinical trial.This article discussed the key point on phase Ⅱ clinical trial design for anticancer drugs,including study population,dose,control group,end point,and so on.We also discussed some novel phase Ⅱ trial designs for molecularly targeted anticancer agents and the method for combination therapy.Hope it can be a useful reference for the researcher who are undertaking new oncology drug development.
-
Protocol Deviations in Clinical Trials of New Drug Application
ZHU Sai-nan,YU Yong-pei,YAN Xiao-yan,YAO Chen
2012-01-01
Abstract:Objective: To reveal the status of protocol deviations in clinical trials of new drug application,and to give reference information to improve the quality of clinical trials.Methods: Thirty six clinical trials of phase II and phase III were collected and the reasons of deviation from design were coded.Results: The deviations were little associated with the basic information of these trials.The most important types were lost(27.73%),not accord with inclusion and exclusion criteria(14.43%),the combined medicine use that influence the efficacy of drugs(14.05%),poor compliance(11.42%),withdrawal because of adverse event(10.92%),and so on.The most important types of deviation affecting population dividing into FAS and PPS were loss of follow-up,and incorrect inclusion and exclusion criteria.For SS,it was lost to follow-up,and the SS set was lost also.Conclusion: Most of the reasons that lead to the plan deviations is associated with the implementation quality of the trials,only a little are related to the characteristics of the drug itself.It is very important to take measures to improve the quality of the study by the sponsors and monitors in their own aspects.
-
Study on the Design of Clinical Trial Protocol for New Drugs
SHAN Ai-lian,QUAN Ju-xiang,LV Yuan
DOI: https://doi.org/10.3969/j.issn.1001-6821.2011.01.012
2011-01-01
Abstract:Objective To investigate the design of clinical trial protocol for new drugs.Methods The study purpose,range and dose of control drugs were involved for discussion the appropriate trial design of these drugs.Results There were some problems of study purpose,selection dose of control drugs and study range.These new drugs have not appeared on the market induced by design failure.The article introduce the some examples in order to offer more information for the investigator and oppraiser.Conclusion Design is the key point of clinical trials.
-
Study on the key steps for the subject medication of phase Ⅰ clinical trials
Tian-ao CHEN,Yan LIANG,Xiao-yan SHENG,Ran XIE,Nan ZHAO,Xia ZHAO,Yi-min CUI,Chang-qing YANG
DOI: https://doi.org/10.13699/j.cnki.1001-6821.2018.07.046
2018-01-01
Abstract:Phase Ⅰ clinical trials are the preliminary tests of clinical pharmacology and human safety evaluation.Majority of the subjects in phase Ⅰ clinical trials are healthy subjects.Besides,there are only a few number of healthy subjects included in one trial.Thus the data requires better accuracy and responsibility.If the subjects do not take medicine appropriately,it will directly affect the results and fail to provide accurate reference for the coming phase Ⅱ,Ⅲ clinical trial.Therefore subject medication is one of the key steps in the conduct of phase Ⅰ clinical trial.This article summarizes and discusses the key steps for oral,injection,inhalation and other delivery methods,to make sure the scientificity,accuracy and objectivity of the test results.This will also ensure the smooth development of late-stage clinical trials.
-
An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics
Patricia M. LoRusso,Scott A. Boerner,Lesley Seymour
DOI: https://doi.org/10.1158/1078-0432.ccr-09-1993
IF: 13.801
2010-03-09
Clinical Cancer Research
Abstract:Phase I clinical trials represent the first step in bringing promising new treatments from the laboratory to the clinic. Although the importance of phase I clinical trials is widely recognized, there is currently no consensus among the scientific, medical, and statistical communities on how best to do these studies in humans. With the advent of targeted therapies, it has become evident that we need to tailor the design of phase I studies for the particular drug class under investigation and any endpoints that are being defined. The National Cancer Institute (NCI) Investigational Drug Steering Committee (IDSC) provides broad external scientific and clinical input on the design and prioritization of early-phase clinical trials with agents for which the NCI Cancer Therapy Evaluation Program (CTEP) holds an Investigational New Drug (IND) application through the U.S. Food and Drug Administration (FDA). The IDSC has formed a number of task forces and working groups, including the Clinical Trial Design Task Force and the Biomarker Working Group, many with membership from within the IDSC as well as external experts, including participants from academia, the pharmaceutical industry, and regulatory authorities. The Clinical Trials Design Taskforce sponsored a Phase I Workshop with the primary goal being to develop consensus recommendations for the optimal design of phase I studies. The primary focus included (1) efficient trial designs, (2) phase I drug combinations, and (3) appropriate statistical and correlative endpoints. In this CCR Focus series, articles summarize key aspects and recommendations on phase I studies (including combination trials), such as design, use of biomarkers, the European Union and Japanese perspectives on design, requirements for first-in-human and other phase I studies, and ensuring regulatory and International Conference on Harmonization (ICH) compliance. A final article summarizes recommendations for the design and conduct of phase II studies.
oncology
-
Discussions on the standardized safety evaluation of new drugs in phase I clinical trials
Min-ji WEI,Shui-qiang WANG,Cai-yun ZHAO,Xu-guang GUO
DOI: https://doi.org/10.13699/j.cnki.1001-6821.2014.10.029
2014-01-01
Abstract:The strategies for pushing phase Ⅰ new drug clinical trials for-ward are based on the ratio of benefit to risk.Thus it would be a good starting to perform a standardized safety evaluation when a new drug enters its early phase trial.In the present paper, we evaluated the safety information contained in the phase I clinical study reports of new drugs and found improvements needed to be done in the following areas , such as the standard terminology used for adverse events , presentation of adverse events, classification of laboratory parameters and special atten -tions to the important and unexpected adverse events , etc.Finally, we proposed to adopt a standardized practice based on Technical Requirements for Registration of Pharmaceuticals for Human Use of International Confer -ence on Harmonization(ICH) guidelines in the assessment of drug safety.
-
Practical Issues in Clinical Inspection Process
Fuyu Song,Xue Qian,Jianming Li,Shein-Chung Chow,Minghuang Hong
DOI: https://doi.org/10.1177/2168479018769887
2019-05-01
Abstract:Regulatory inspection of clinical trial is necessary in order for (1) assessing compliance with statutory requirements and regulatory requirement governing the conduct of clinical trials and (2) verifying the accuracy and reliability of clinical trial data submitted to regulatory agencies such as the United States Food and Drug Administration (FDA) in support of research or marketing applications. This article provides an overview of clinical inspection process and issues that are commonly encountered during the conduct of clinical trials. In addition, a couple of sampling plans for clinical inspection of relatively large trials are proposed. The proposed statistical process for clinical inspection that will achieve a desired degree of inspection accuracy and reliability is useful when the resources of inspectors are limited. The proposed 2-stage sampling plan can be applied to clinical inspection for multicenter and/or multinational multicenter clinical trials.
pharmacology & pharmacy,medical informatics
-
Discussion on problems in conducting the clinical trials on off-label use of drug
Xiao-quan HUANG,Shi-yao CHEN
DOI: https://doi.org/10.3969/j.issn.1672-8157.2017.01.018
2017-01-01
Abstract:Off-label prescriptions are common in clinical practice, and its relative researches increase globally over time. However, a lot of problems remain in conducting the clinical trials on off-label drug use. The aim of this article was to discuss how to conduct clinical trials on off-label use of drugs and its remaining problems. The problems were discussed as follows: when to conduct the off-label drug clinical trial; the controversy about who should be the investigators; whether the CFDA (China Food and Drug Administration) license is required for conducting such trials; how to obtain the permission from Clinical Ethics Committee; how to register the clinical trials on off-label use of drug; how to gain the funding supports; how to have your patients' consent; how to select a suitable patient population; and how to conduct study design of clinical trial on off-label use of drug. Detailed interpretations were made into these questions. We hope to standardize the off-label medication, conduct the proper clinical trial on off-label drug use, and reduce the occurrence of adverse events.
-
Design study of pharmacokinetics and comparison of 4 kinds of the clinal trial phase Ⅱ design of roxithromycin/ambroxol hydrochloride compound tablets
Ai-lian SHAN,Ju-xiang QUAN,Min-ji WEI,Yuan Lü
DOI: https://doi.org/10.3969/j.issn.1001-6821.2007.05.015
2007-01-01
Abstract:Objective To investigate the reasonableness of efficacy index and indication selection by comparing 4 phase II clinical trial designs of roxithromycin/ambroxol tablets. Methods Different clinical protocols of roxithromycin/ambroxol tablets were collected and comparisons among them were made.Results Based on the human pharmacokinetics of roxithromycin/ambroxol, the fourth protocol was regarded as the most reasonable design.Conclusion In design of a phase II clinical trial with compound preparation like roxithromycin/ambroxol, the mechanism of action and pharmacokinetic characteristics of each drug in a preparation should be considered,and collective evaluation should be given including the determination of sample size.
-
Consideration on Nonclinical Evaluation for the Conduct of Human Clinical Trails and Marketing Authorization for New Anticancer Drugs
王海学,陈晓媛,钱思源,彭健
DOI: https://doi.org/10.3969/j.issn.1001-6821.2009.02.026
2009-01-01
Abstract:Nonclinical evaluation can be involved in the whole process of clinical trail and marketing application.International conference on harmonization(ICH) drafted a step 2 guidance(M3)with nonclinical evaluation for the conduct of human clinical trails and marketing authorization for pharmaceutics.As for anticancer drugs,ICH M3 indicated that,pharmaceuticals under development for indications in life threatening or serious diseases(e.g.,advanced cancer,) without current effective therapy might do as case-bycase approach.This article discussed the nonclinical evaluation consideration for oncology drugs,which will give some suggestions for new anticancer drug research and evaluation.
-
Incorporating Historical Information to Improve Phase I Clinical Trials
Yanhong Zhou,J. Jack Lee,Shunguang Wang,Stuart Bailey,Ying Yuan
DOI: https://doi.org/10.1002/pst.2121
2021-01-01
Pharmaceutical Statistics
Abstract:Incorporating historical data or real-world evidence has a great potential to improve the efficiency of phase I clinical trials and to accelerate drug development. For model-based designs, such as the continuous reassessment method (CRM), this can be conveniently carried out by specifying a "skeleton," i.e., the prior estimate of dose limiting toxicity (DLT) probability at each dose. In contrast, little work has been done to incorporate historical data or real-world evidence into model-assisted designs, such as the Bayesian optimal interval (BOIN), keyboard, and modified toxicity probability interval (mTPI) designs. This has led to the misconception that model-assisted designs cannot incorporate prior information. In this paper, we propose a unified framework that allows for incorporating historical data or real-world evidence into model-assisted designs. The proposed approach uses the well-established "skeleton" approach, combined with the concept of prior effective sample size, thus it is easy to understand and use. More importantly, our approach maintains the hallmark of model-assisted designs: simplicity---the dose escalation/de-escalation rule can be tabulated prior to the trial conduct. Extensive simulation studies show that the proposed method can effectively incorporate prior information to improve the operating characteristics of model-assisted designs, similarly to model-based designs.
-
Bayesian Optimal Phase II Design for Randomized Clinical Trials
Yujie Zhao,Bo Yang,J. Jack Lee,Li Wang,Ying Yuan
DOI: https://doi.org/10.1080/19466315.2022.2050290
2022-01-01
Statistics in Biopharmaceutical Research
Abstract:Randomized clinical trials are the gold standard to evaluate the efficacy of an experimental treatment. We propose a flexible Bayesian optimal phase II (BOP2) design for two-arm randomized trials. The proposed two-arm BOP2 design is flexible and can handle single, multiple primary and coprimary endpoints for superiority and noninferiority trials under a unified framework. It also allows users to specify the number and timing of interim analyses to meet clinical needs. While enjoying the flexibility of Bayesian adaptive designs, the two-arm BOP2 design explicitly controls the Type I error rate and is optimal for maximizing power, thereby ensuring desirable frequentist operating characteristics. Another feature of the two-arm BOP2 design is that its decision rule can be tabulated and included in the trial protocol prior to trial commence. To conduct the trial, no complicated Bayesian calculation is needed; clinicians can simply look up the table and make go/no-go decisions. Simulation studies show that the two-arm BOP2 design has desirable operating characteristics. Easy-to-use online application is freely available at www.trialdesign.org to facilitate the use of the two-arm BOP2 design in clinical trials.
-
Statistical Considerations in Design of Clinical Trial for Fixed Dose Drug Combination
Chen Yao
2011-01-01
Abstract:Development of new fixed dose drug combination is more and more popular in pharmaceutical industry.A scientific and reasonable design of clinical trial is the key point for the drug approval by the authority.This paper,which is based on the procedure of new drug application,introduces the design types of the clinical trials for new fixed dose combination in dose-finding period and confirmation period.Then the necessity of factorial design and placebo is explained in detail.
-
Duffy blood group phenotype–genotype correlations using high‐resolution melting analysis PCR and microarray reveal complex cases including a new null FY*A allele: the role for sequencing in genotyping algorithms
G. Lopez,J. Morrison,J. A. Condon,Brett Wilson,J. R. Martin,Y. Liew,R. Flower,Catherine A Hyland
DOI: https://doi.org/10.1111/vox.12273
2015-10-01
Vox Sanguinis
Abstract:Duffy blood group phenotypes can be predicted by genotyping for single nucleotide polymorphisms (SNPs) responsible for the Fya/Fyb polymorphism, for weak Fyb antigen, and for the red cell null Fy(a−b−) phenotype. This study correlates Duffy phenotype predictions with serotyping to assess the most reliable procedure for typing.
-
Expert Consensus on Key Issues of Quality Control in Clinical Trials of New Drugs of Traditional Chinese Medicine
Wei-An Yuan,Jian-Yuan Tang,Rui Gao,Si-Yuan Hu,Yan-Ling Zhao,Chong Zou,Bo Li,Jun-Hua Zhang,Lei Zhang,Zhong-Qi Yang
DOI: https://doi.org/10.19540/j.cnki.cjcmm.20210219.501
2021-01-01
Abstract:Since "the implementation of good clinical practice"(GCP), especially after 2015, the overall quality of new drug cli-nical trials in China has made significant progress, but compared with developed countries, there are still some obvious quality problems in clinical trials in China. Clinical trials of new drugs of traditional Chinese medicine are an important part of clinical trials of new drugs in China. In addition to some common problems in all clinical trials, there are also some special quality problems. In terms of security data, such as the collection of human safety data is not standardized, the management and judgment of unexpected serious adverse reactions(SUSAR) were not professional and timely, the relationship between adverse events and trial drug was not fully judged by investigator, In terms of effective data, such as primary efficacy outcome of the scale cannot be traced, TCM syndrome data cannot meet the requirements of "source data" in the revised GCP and the quality of traditional Chinese medicine placebo is not high, in terms of overall quality system construction, the sponsors and research institutions have not established a quality assurance system that conforms to the characteristics of new drug research of traditional Chinese medicine, etc. The quality of clinical trials of new drugs of traditional Chinese medicine is based on the current GCP and ICH-GCP in China, we should also consider the characteristics of clinical trials of new traditional Chinese medicine drugs, and formulate targeted quality control measures according to the characteristics of these new drugs of traditional Chinese medicine, to improve the overall quality of clinical trials of new drugs of traditional Chinese medicine in China, which has important strategic significance for promoting the research and development of new drugs of traditional Chinese medicine in China.
-
An Intelligent Information Dictionary for Semantic Manipulation of Relational Databases
Stephanie J. Cammarata
DOI: https://doi.org/10.1007/3-540-19074-0_55
1988-03-14
Abstract:
-
Analysis of clinical trials supported by foreign pharmaceutical industries in China
Chen Yao,Keiichi Sugino,Yasuo Ohashi,Qian Gong
2008-01-01
Abstract:Objective: To summarize and analyze the status of clinical trials in China using the data from "ClinicalTrials.gov" database. Methods: "ClinicalTrials.gov" provides regularly up-to-date information on federally and privately supported clinical research in human volunteers. It is the biggest clinical trial registry database all over the world. The worldwide information on clinical trials (including all data about China) was collected from "ClinicalTrials.gov". Results: The number of clinical trials, which were supported by industry by now, was 97 in China. Among the trials, there were 58 multinational clinical trials, and 39 clinical trials conducted only in China. The most popular diseases were cancer, circulation system disorders, central nervous system disorders and infection diseases. All of the drugs used for clinical trials conducted only in China were already marketed in a foreign country, so all the clinical trials were conducted either for seeking new indications or for import. On the other hand, drugs used for multinational clinical trials were those developed in phase 3 or in phase 4 in a foreign country; the aims were to gain Chinese data or to promote marketing. Half of the trials conducted only in China and 67% trials conducted multinationally were double blind, randomized trials. Most of the clinical trials in China, either the ones conducted only in China or multinational ones, were conducted in about 10 units. Conclusion: The foreign pharmaceutical industries let Chinese take part in a lot of clinical trials in order to develop a new medicine rapidly.
-
Main principles of designing clinical trial of drugs
Yang Fu-de
DOI: https://doi.org/10.3321/j.issn:1673-8225.2006.44.054
2006-01-01
Abstract:AIM:To develop clearly the main principles and methods of drug clinical trials.METHODS:A comprehensive medical literature research was performed by computer,and the methods and principles of designing drug clinical trials were introduced combining with the health statistical principle.RESULTS:①Three principles:Control,randomization and replication.②Seven controlled methods:Blank control,placebo control,experimental condition control,standard control,auto-control and cross-over auto-control,before-after control of different cases(historical control),without control study.③Four controlled methods of false positive and false negative mistakes:Precise evaluation of the sample amount and avoid sampling error;Reliable and specific diagnosis standard as well as inclusive and exclusive criteria to select study subjects;Blindness method was used to collect data,and control information bias;Uniform therapeutic project,observing marker and method were confirmed.CONCLUSION:Scientific and strict clinical trials of drugs are helpful to obtain actual and reliable research results.